SCLC

2
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Design Therapeutics
1 program
1
Topotecan - usualPhase 2/31 trial
Active Trials
NCT07145333Active Not RecruitingEst. Oct 2026
Zai Lab
Zai LabCA - South SF
1 program
1
ZL-1310Phase 11 trial
Active Trials
NCT06179069Recruiting112Est. Jul 2027
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
SRSN/A1 trial
Active Trials
NCT03297788Completed56Est. Dec 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Design TherapeuticsTopotecan - usual
Zai LabZL-1310
Heidelberg PharmaSRS

Clinical Trials (3)

Total enrollment: 168 patients across 3 trials

NCT07145333Design TherapeuticsTopotecan - usual

Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms

Start: Aug 2025Est. completion: Oct 2026
Phase 2/3Active Not Recruiting
NCT06179069Zai LabZL-1310

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

Start: Jan 2024Est. completion: Jul 2027112 patients
Phase 1Recruiting
NCT03297788Heidelberg PharmaSRS

Whole Brain Radiation Therapy Alone vs. Radiosurgery for SCLC Patients With 1-10 Brain Metastases

Start: Dec 2017Est. completion: Dec 202356 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 168 patients
3 companies competing in this space